Tvardi Therapeutics (TVRD) Stock Price & Analysis
TVRD Stock Chart & Stats
- Day’s Range
- N/A
- 52-Week Range
- N/A
- Previous Close
- N/A
- Volume
- N/A
- Average Volume (3M)
- N/A
- Market Cap
- CHF 8.71M
- Enterprise Value
- CHF 2.20M
- Total Cash (Recent Filing)
- CHF 15.77M
- Total Debt (Recent Filing)
- CHF 145.00K
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- Nov 12, 2026 (Est.)
- EPS Estimate
- -0.47
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Targeted Clinical Pipeline
A focused oral pipeline targeting STAT3-driven signaling gives Tvardi a coherent therapeutic strategy across cancer and fibrosis. If clinical validation continues, the shared biological target and multiple indications could support platform leverage and create several opportunities from one core technology.
Early Clinical Progress
Demonstrated target engagement and improved tolerability in Phase 1 provide important early validation for TTI-109. These findings can improve the program’s ability to advance into later development, support broader clinical testing, and strengthen the potential value of the company’s STAT3-focused pipeline.
Low Current Debt
Minimal current debt reduces interest burden and near-term leverage pressure, preserving more flexibility for clinical investment and corporate decisions. Although the company remains dependent on funding, its present capital structure is not burdened by substantial debt obligations that could compete with research spending.
Bears Say
No Current Revenue
The complete disappearance of reported revenue indicates that Tvardi currently lacks a commercial revenue base to support operations. This leaves the company dependent on successful clinical development and future financing rather than internally generated sales, increasing the importance of pipeline execution over the next several quarters.
Persistent Cash Burn
Sustained negative operating and free cash flow means clinical programs are consuming cash rather than funding themselves. Even though burn improved versus 2023–2024, the continuing outflow implies reliance on external funding to maintain operations and creates ongoing financing risk if development spending continues.
Shrinking Assets And Equity History
The sharp reduction in total assets, combined with a recent history of negative equity, points to limited financial resilience despite low current debt. This history can constrain the company’s ability to absorb setbacks, fund multiple programs, or sustain development without additional capital and balance-sheet support.
Tvardi Therapeutics News
TVRD FAQ
What is Tvardi Therapeutics’s market cap?
When is Tvardi Therapeutics’s upcoming earnings report date?
How were Tvardi Therapeutics’s earnings last quarter?
Is Tvardi Therapeutics overvalued?
Does Tvardi Therapeutics pay dividends?
What is Tvardi Therapeutics’s EPS estimate?
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Tvardi Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Imran Alibhai
- Employees
- 12
- Website
- tvarditherapeutics.com
- Address
- 3 Sugar Creek Center Boulevard, Sugar Land, TX, 77478, US
Tvardi Therapeutics (TVRD) Earnings & Revenues
TVRD Earnings Call
Earnings Call SentimentNeutral
The earnings call highlighted a strategic focus on a promising NP program with potential for significant clinical and commercial success. However, challenges with KORSUVA revenue and increased R&D expenses were notable concerns.
View all CH:TVRD earnings summaries